Navigation Links
Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Date:12/4/2009

EMERYVILLE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting.

The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 25914947. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25914947 later in the day. The replay will be available on the Onyx website through January 7, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... excited to announce the launch of its Mediceutical line of products, a line of ... of clinical conditions. Founded in 2013, Forté spent more than two years researching and ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a ... Tidelands Health, a three hospital system in South Carolina, to provide its secure ... for technology that enhances communication, drives workflow efficiencies and improves provider and patient ...
(Date:5/3/2016)... ... 2016 , ... Nationally recognized personal injury law firm Monge & Associates is honoring ... anyone who wants one for their Mother or any other mother figure. , According to ... Mothers.” Monge goes on to say, “we are choosing to do this by giving ...
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
(Date:5/3/2016)... ... 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick Pospisil, now ... used to diagnose and treat joint problems. During this procedure, Dr. Pospisil makes a ... lighting system and lens that illuminate and magnify the various structures in the joint ...
Breaking Medicine News(10 mins):